Skip to main content

Loading market data...

EXEL

Exelixis, Inc.

NASDAQ • United states

$64.39

+$1.71

(+2.73%)

Source: Yahoo Finance · Quote time Oct 20, 2026 20:00 GMT+0000

Catalyst Evidence

No verified catalyst stored yet

Click “View” to see the stored chain of evidence (if available).

Management
Credibility
Score

Exelixis, Inc. (EXEL)

Unavailable

Quotes may be delayed

$15.95B

Market Cap

2,135,733

Volume

18.5

P/E Ratio

Unavailable

Div Yield

Exelixis, Inc. Price Chart

Loading price history…

Management Credibility Analysis

Unavailable

Verified Management Score Unavailable

Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed

Verified Catalysts Unavailable

No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive: Not disclosed
Headquarters: 1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Founded: Not disclosed

📈 Company Timeline

Major business events

Positive

Negative

Neutral

11 Sep 2026

Exelixis, Inc. reported Another company event

Exelixis, Inc. filed an 8-K covering another company event.

31 Aug 2026

Exelixis, Inc. reported Another company event

Exelixis, Inc. filed an 8-K covering another company event.

14 Aug 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Exelixis, Inc..

12 Aug 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Exelixis, Inc..

5 Aug 2026

Exelixis, Inc. securities registration filing

Exelixis, Inc. filed a registration or prospectus document concerning securities.

Capital Structure & Financial Position

Financial strength and liquidity analysis

Cash and equivalents (USD)$281.45M

Total assets (USD)$2.49B

Total liabilities (USD)$650.47M

Shareholders' equity (USD)$1.84B

Long-term debt (USD)$0

Debt due within a year (USD)$189.12M

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated 3 Jul 2026

Peer Comparison - Health Care

Company	Price	Market Cap
LLY - Eli Lilly and Company	$1,276.13 Yahoo Finance	$1.20T
JNJ - Johnson & Johnson	$256.74 Yahoo Finance	$618.71B
ABBV - AbbVie Inc.	$284.80 Yahoo Finance	$503.28B
UNH - UnitedHealth Group Incorporated	$418.43 Yahoo Finance	$375.58B
MRK - Merck & Co., Inc.	$148.55 Yahoo Finance	$366.50B

📋 Corporate Actions

Recent and upcoming corporate events

Verified Corporate Actions Unavailable

Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis

Quarter	Revenue (USD)	Operating income	Net income	Diluted EPS (USD)	Filed
Q2 2026	$628.69M	$248.41M	$212.05M	$0.82	10-Q · 5 Aug 2026
Q1 2026	$610.81M	$251.34M	$210.47M	$0.79	10-Q · 5 May 2026
Q4 2025	$598.66M	$235.22M	$244.56M	Unavailable	10-K · 10 Feb 2026
Q3 2025	$597.76M	$236.54M	$193.58M	$0.69	10-Q · 4 Nov 2025
Q2 2025	$568.26M	$213.58M	$184.85M	$0.65	10-Q · 5 Aug 2026
Q1 2025	$555.45M	$186.86M	$159.62M	$0.55	10-Q · 5 May 2026

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Neutral

Target: $53.45

-17.0% upside potential

📈

Strong Buy

Unavailable

👍

Buy

4

⏸️

Hold

8

📉

Sell

1

13 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved 21 Oct 2026, 06:47 UTC Targets range 41.00–65.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments

Verified Dividend Data Unavailable

Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable

Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity

10

Aug 2026

Beckerle Mary C

Director

Open-market sale

$53.66 per share

9,812 shares

1

Jun 2026

WYSZOMIERSKI JACK L

Director

Open-market sale

$50.55 per share

3,925 shares

1

Jun 2026

Eckhardt Sue Gail

Director

Open-market sale

$50.14 per share

9,812 shares

27

May 2026

PAPADOPOULOS STELIOS

Director

Grant or award

Unavailable per share

8,367 shares

27

May 2026

Heyman Tomas J.

Director

Grant or award

Unavailable per share

8,367 shares

27

May 2026

Eckhardt Sue Gail

Director

Grant or award

Unavailable per share

8,367 shares

27

May 2026

Smith Julie

Director

Grant or award

Unavailable per share

8,367 shares

27

May 2026

Freire Maria C

Director

Grant or award

Unavailable per share

8,367 shares

Top Shareholders

Blackrock, Inc.

29,075,377 shares

-5.649% change

6/30/2026

Vanguard Group Inc

25,490,449 shares

-2.203% change

12/31/2025

Farallon Capital Management, L.L.C.

13,468,010 shares

2.723% change

6/30/2026

Renaissance Technologies Llc

13,427,993 shares

-2.178% change

6/30/2026

Vanguard Portfolio Management Llc

12,043,122 shares

-0.349% change

6/30/2026

Aqr Capital Management Llc

11,023,943 shares

-15.82% change

6/30/2026

Vanguard Capital Management Llc

10,950,997 shares

-2.735% change

6/30/2026

State Street Corp

9,970,071 shares

-3.189% change

6/30/2026

Fuller & Thaler Asset Management, Inc.

8,929,389 shares

4.532% change

6/30/2026

Lsv Asset Management

8,146,478 shares

5.174% change

6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed 21 Oct 2026, 06:47 UTC· 23 hours ago

Research coverage and investment tools

Exelixis, Inc. (EXEL) is a stock listed on the Nasdaq in the United States, in the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)). Its last price was US$64.39 on 20 Oct 2026. That is 100% of the way from its 52-week low of US$34.63 to its 52-week high of US$64.42. Its market capitalisation was US$15.95 billion at that price.

Watch Add to portfolio Set an alert Compare Position size

How position sizing works Dividend yield and total return

Quarter	Revenue	Operating income	Net income	Diluted EPS	Gross margin	Operating margin	Free cash flow	Filed
Q2 2026	$628.69M	$248.41M	$212.05M	$0.82	—	39.5%	—	10-Q · 5 Aug 2026 (opens in a new tab)
Q1 2026	$610.81M	$251.34M	$210.47M	$0.79	—	41.1%	$250.34M	10-Q · 5 May 2026 (opens in a new tab)
Q4 2025	$598.66M	$235.22M	$244.56M	Unavailable	—	39.3%	—	10-K · 10 Feb 2026 (opens in a new tab)
Q3 2025	$597.76M R (restated)	$236.54M R (restated)	$193.58M R (restated)	$0.69 R (restated)	—	39.6%	—	10-Q · 4 Nov 2025 (opens in a new tab)
Q2 2025	$568.26M R (restated)	$213.58M R (restated)	$184.85M R (restated)	$0.65 R (restated)	—	37.6%	$208.49M	10-Q · 5 Aug 2026 (opens in a new tab)
Q1 2025	$555.45M	$186.86M	$159.62M	$0.55	—	33.6%	$208.49M	10-Q · 5 May 2026 (opens in a new tab)

Cash and equivalents: $281.45M
Total assets: $2.49B
Total liabilities: $650.47M
Shareholders' equity: $1.84B
Long-term debt: $0
Debt due within a year: $189.12M

8-K · 11 Sep 2026

Exelixis, Inc. reported Another company event (opens in a new tab)

Exelixis, Inc. filed an 8-K covering another company event.
8-K · 31 Aug 2026

Exelixis, Inc. reported Another company event (opens in a new tab)

Exelixis, Inc. filed an 8-K covering another company event.
SCHEDULE 13D/A · 14 Aug 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in Exelixis, Inc..
SCHEDULE 13G/A · 12 Aug 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in Exelixis, Inc..
S-8 · 5 Aug 2026

Exelixis, Inc. securities registration filing (opens in a new tab)

Exelixis, Inc. filed a registration or prospectus document concerning securities.

Insider	Date	Transaction	Shares	Average price	Filing
Beckerle Mary C Director	10 Aug 2026	Open-market sale (S)	−9,812	$53.66	Form 4 (opens in a new tab)
WYSZOMIERSKI JACK L Director	1 Jun 2026	Open-market sale (S)	−3,925	$50.55	Form 4 (opens in a new tab)
Eckhardt Sue Gail Director	1 Jun 2026	Open-market sale (S)	−9,812	$50.14	Form 4 (opens in a new tab)
PAPADOPOULOS STELIOS Director	27 May 2026	Grant or award (A)	+8,367	—	Form 4 (opens in a new tab)
Heyman Tomas J. Director	27 May 2026	Grant or award (A)	+8,367	—	Form 4 (opens in a new tab)
Eckhardt Sue Gail Director	27 May 2026	Grant or award (A)	+8,367	—	Form 4 (opens in a new tab)
Smith Julie Director	27 May 2026	Grant or award (A)	+8,367	—	Form 4 (opens in a new tab)
Freire Maria C Director	27 May 2026	Grant or award (A)	+8,367	—	Form 4 (opens in a new tab)

Institution	Report date	Shares	Change
Blackrock, Inc.	6/30/2026	29,075,377	-5.649%
Vanguard Group Inc	12/31/2025	25,490,449	-2.203%
Farallon Capital Management, L.L.C.	6/30/2026	13,468,010	2.723%
Renaissance Technologies Llc	6/30/2026	13,427,993	-2.178%
Vanguard Portfolio Management Llc	6/30/2026	12,043,122	-0.349%
Aqr Capital Management Llc	6/30/2026	11,023,943	-15.82%
Vanguard Capital Management Llc	6/30/2026	10,950,997	-2.735%
State Street Corp	6/30/2026	9,970,071	-3.189%
Fuller & Thaler Asset Management, Inc.	6/30/2026	8,929,389	4.532%
Lsv Asset Management	6/30/2026	8,146,478	5.174%

Previous close: 62.68 USD
Day range: 62.85 – 64.42 USD
52-week range: 34.63 – 64.42 USD
Volume: 2,135,733
Market cap: $15.95B
Average volume: 2,183,522
P/E ratio: 18.5
EPS (FY 2025, diluted): 2.78 USD
Shares outstanding: 247.78M
Beta (5Y monthly): 0.45

Price, ranges and volume: Yahoo Finance (opens in a new tab) Observed 20 Oct 2026, 20:00 UTC· 1 day ago

Average volume and shares: Nasdaq (opens in a new tab) Observed 22 Oct 2026, 06:18 UTC· 14 minutes ago

P/E is market cap ÷ trailing 12-month net income from SEC filings.

EPS: SEC EDGAR company facts (opens in a new tab)

Beta: 5 years of monthly returns against the S&P 500, calculated from Yahoo Finance prices. Market cap is the price × shares outstanding.

This research is not available for EXEL yet

Guidance history

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.